Dako and Amgen Expand Collaboration with Plan to Develop New Diagnostic Test
GLOSTRUP, Denmark, Feb. 11, 2014
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced a new project with Amgen to develop a molecular diagnostic test using Dako's IQFISH hybridization buffer.
"We are pleased to continue our work with Amgen, particularly within the molecular arena," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. "We are excited to expand this collaboration into even more projects."
The cutting-edge IQFISH hybridization buffer, introduced by Dako in 2012, reduces diagnostic test turnaround time from 17 hours to just 3.5 hours. It enables pathology labs-for the first time-to run DNA-based hybridization assays quickly, with distinct and higher fluorescent signal intensity compared to traditional FISH assays. This ability represents a major advance for pathologists, oncologists and ultimately patients.
Companion diagnostics are becoming increasingly important in treating disease. They provide a way to both improve patient care and reduce health-care costs by matching specific therapies to the individuals most likely to benefit from them, since all patients do not respond in the same way.
Dako partners with top-tier pharma companies for the development of companion diagnostics. Its track record in companion diagnostics continues to attract new partners, as well as add new projects with current partners.
About Dako - An Agilent Technologies Company
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako became part of Agilent Technologies in 2012.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
# # #
Maia Fredtoft Søchting
+45 25 46 10 83